Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06380062 Completed - Clinical trials for Benign Prostatic Hyperplasia

Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia

Start date: January 12, 2012
Phase:
Study type: Observational

The aim of this study was to investigate plasma concentrations of one-carbon metabolites and phospholipid classes in participants with primary prostate cancer and those with benign hyperplasia. Moreover, the metabolites were studied in relation to tumor grade and age.

NCT ID: NCT06319469 Completed - Clinical trials for Prostatic Hyperplasia

The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Acute urine retention, AUR, is often considered the most serious consequence of aging men with progressive benign prostatic hyperplasia (BPH). AUR is defined as the sudden and painful inability to void freely. This study aims to evaluate whether pyridostigmine bromide added to silodosin is beneficial in treating acute urine retention caused by BPH.

NCT ID: NCT06315062 Completed - Clinical trials for Benign Hyperplasia of Prostate

Efficacy of Rezum® in Reducing Prostate Volume

Start date: January 1, 2020
Phase:
Study type: Observational

This study aimed to assess the efficacy of Rezum® water vapor therapy in reducing prostate volume in patients aged 40 years or older with Benign Prostate Hyperplasia (BPH) at UNIBE Hospital in Costa Rica. A retrospective analysis will be conducted on 289 patient records, focusing on prostate volume, International Prostate Symptom Score (IPSS), and urinary flow rate. Statistical analyses included two-sample mean comparisons, effect size estimation, and linear regression.

NCT ID: NCT06282731 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Changes of Urine Growth Factors Level

Start date: May 31, 2013
Phase: Early Phase 1
Study type: Interventional

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.

NCT ID: NCT06263049 Completed - Clinical trials for Benign Prostatic Hyperplasia

Is Ejaculation Preservation TURis the Natural Evolution of the "Gold Standard".

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

evaluation of the impact of apical urethral mucosa sparring with the urethra around the verumontanum on the ejaculatory function and early postoperative urinary incontinence

NCT ID: NCT06260917 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Effect of Urinating Through the Zipper or by Pulling Down the Trousers on Uroflowmetry Parameters in LUTS

Start date: November 1, 2023
Phase:
Study type: Observational

There are many factors that affect uroflowmetry parameters. One of these is the urination position. Research has mostly focused on standing and sitting urination positions. However, those who prefer the standing position as a habit can urinate by opening the zipper or lowering the trousers. Although the effect of these two applications on uroflowmetry parameters in healthy men has been investigated in only one study, their effect on patients with lower urinary tract symptoms has not been examined.

NCT ID: NCT06257654 Completed - Clinical trials for Prostatic Hyperplasia

One-year Results After Single-center Water Vapor Thermal Therapy for Symptomatic Benign Prostatic Hyperplasia.

Start date: January 1, 2021
Phase:
Study type: Observational

Objective: Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. The investigators sought to determine whether Rezūm is effective in the treatment of catheter-dependent urinary retention secondary to BPH.

NCT ID: NCT06167122 Completed - Clinical trials for Craniofacial Fibrous Dysplasia

Treatment Protocol and Long-Term Outcomes in Craniofacial Fibrous Dysplasia

CFD
Start date: March 1, 2020
Phase:
Study type: Observational

Craniofacial fibrous dysplasia (CFD) is a nonneoplastic disease characterized by fibro-osseous lesions in the affected bones. Treatment is mainly surgical and is stratified based on four different anatomical zones. This study aimed to evaluate the long-term outcomes and refine the algorithm for CFD.

NCT ID: NCT06153043 Completed - Clinical trials for Classic Congenital Adrenal Hyperplasia

Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia

FERTI-HCS
Start date: January 16, 2024
Phase:
Study type: Observational

Classic congenital adrenal hyperplasia (CAH) is a rare genetic endocrine disorder. Its prevalence is around 1/15.000. It results from a deficiency in 21-hydroxylase, an adrenal steroidogenic enzyme involved in the biosynthesis of cortisol and aldosterone. Enzyme deficiency in the steroideogenesis pathway leads to cortisol and aldosterone deficiency of varying severity, and to the accumulation of precursors (17OHP and Progesterone), which are diverted to the production of androgens (Testosterone and D4AD). There are two clinical forms of classical CAH : the salt wasting form and the simple virilizing form, depending on the degree of aldosterone deficiency. The clinical signs are adrenal insufficiency and hyperandrogenism. Hyperandrogenism manifests itself during foetal life, and may be responsible for virilization of the external genitalia of a female foetus, of varying severity. The challenge in managing this condition is to find the right therapeutic balance. Hydrocortisone and fludrocortisone supplementation must be adapted to control adrenal insufficiency, and limit hyperandrogenism. It must be sufficient to avoid episodes of acute adrenal insufficiency, but not excessive to avoid complications secondary to hypercorticism. During childhood, this balance is necessary for growth and pubertal development. However, this balance is difficult to achieve and maintain over time. In adulthood, the fertility of patients is an important issue. This one remains poorly understood. It was only after the introduction of cortisol supplementation in the treatment of CAH in the 1950s that the first pregnancies were described. Since when, due to the rarity of the pathology, the number of pregnancies studied has remained low, and the literature has little hindsight on the subject. This pathology has long been associated with female infertility, due to many factors : biological, mechanical, psychological and sexual, among others. Biological hyperandrogenism may be responsible for chronic dysovulation, and may render the endometrium unsuitable for embryonic implantation. The virilization of the external genitalia and possible complications of pelvic surgery can be an obstacle to sexuality in these patients. They experience sexual difficulties, particularly during penetrative intercourse. The literature also shows that the majority of these patients are single and that their sexual orientation is more likely to be homosexual. Finally, the desire to have children is less prevalent in these patients than in the general population. The first published studies on the fertility of CAH patients showed a lower pregnancy rate than the general population, but did not take into account the patient' desire to become pregnant. In 2009, Casteras et al demonstrated for the first time in a cohort of CAH patients that fecundity is preserved in patients with a desire to become pregnant. It should be noted that the fertility of patients with CAH may evolve in the coming years in France thanks to the new bioethics law voted in 2021, which now allows unmarried patients and patients in homosexual couples to have access to male gamete donation. In addition, very little is known about the course of pregnancies in patients with CAH. Few pregnancies have been studied to date. Hormonal balance during pregnancy if difficult to monitor, given the absence of reliable biological makers during this period. In this context, it is complicated to know the impact of the pathology and its balance on the course of the pregnancy. The latest articles published on the subject of pregnancy complications are contradictory. Some find an increased risk of gestational diabetes. Others find a higher risk of maternal-fetal infection, low weight for gestational age, or congenital malformations than in general population. The increased risk of miscarriage is debated. On the other hand, articles are unanimous on the most frequent mode of delivery in this population : in the vast majority of cases, patients give birth by ceasarian section, due to their history of pelvic surgery. It is in context that we wish through this study to make a point of fertility and pregnancy in patients with classical CAH.

NCT ID: NCT06148259 Completed - Diabetes Mellitus Clinical Trials

SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes

Start date: March 12, 2021
Phase: N/A
Study type: Interventional

The study aims to compare the effect of two different classes of anti- diabetes medications on prostate volume and symptoms in elderly patients with diabetes mellitus